IS ZYNERBA PHARMACEUTICALS, INC. (ZYNE) A KEEPER?
By Melissa Arnold - May 16, 2019
80
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) went up by 5.30% from its latest closing price when compared to the 1-year high value of $13.63, while ZYNE stocks collected +13.82% of gains with the last five trading sessions.
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) Worth an Investment?
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) The 36 Months beta value for ZYNE stocks is at 5.56, while 5 of the analysts out of 6 who provided ratings for Zynerba Pharmaceuticals, Inc. stocks as a “buy” while 0 as overweight, 1 rated it as hold and 0 as sell. The average price we get from analysts is $20.08 which is $6.16 above current price. ZYNE currently has a short float of 19.09% and public float of 18.12M with average trading volume of 2.26M shares.
ZYNE Market Performance
ZYNE stocks went up by 13.82% for the week, with the monthly jump of 66.71% and a quarterly performance of 156.35%, while its annual performance rate touched 47.46%. The simple moving average for the period of the last 20 days is 25.11% for ZYNE stocks with the simple moving average of 119.97% for the last 200 days.
Analysts’ Opinion on Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
Many brokerage firms have already submitted their reports for ZYNE stocks, with Canaccord Genuity repeating the rating for ZYNE shares by setting it to “Buy”. The predicted price for ZYNE socks in the upcoming period according to Canaccord Genuity is $9 based on the research report published on April 22, 2019.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see ZYNE stock at the price of $23. The rating they have provided for ZYNE stocks is “Buy” according to the report published on February 1, 2018.
Ladenburg Thalmann gave “Buy” rating to ZYNE stocks, setting the target price at $25.50 in the report published on January 29, 2018.
ZYNE Stocks 70.07% Far from 50 Day Moving Average
After a stumble in the market that brought ZYNE to its low price for the period of the last 52 weeks, Zynerba Pharmaceuticals, Inc. was able to take a rebound, for now settling with 2.13% of profit for the given period.
The stock volatility was left at 10.88%, however, within the period of a single month, the volatility rate increased by 7.63%, while the shares surge at the distance of +67.71% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by +180.08% upper at the present time.
In the course of the last 5 trading sessions, ZYNE went up by +13.82%, which changed the moving average for the period of 200 days to the total of +97.45% of gains for the stock in comparison to the 20-day moving average settled at $11.41. In addition, Zynerba Pharmaceuticals, Inc. saw 368.69% in overturn over the period of a single year with a tendency to cut further gains.
ZYNE Stock Insider Trading
Reports are indicating that there were more than several insider trading activities at Zynerba Pharmaceuticals, Inc. (ZYNE), starting from Butler John P., who bought 5,000 shares at the price of $6.43 back on Aug 22. After this action, Rushing now owns 5,000 shares of Zynerba Pharmaceuticals, Inc., valued at $32,153 with the latest closing price.
ANIDO ARMANDO, the Chairman & Chief Exec. Officer of Zynerba Pharmaceuticals, Inc., bought 15,000 shares at the value of $5.96 during a trade that took place back on Aug 06, which means that ANIDO ARMANDO is holding 352,512 shares at the value of $89,423 based on the most recent closing price.
ZYNE Stock Fundamentals
The current profitability levels are settled at -46974.22 for the present operating margin. The net margin for Zynerba Pharmaceuticals, Inc. stands at -46408.34. Total capital return value is set at -68.15, while invested capital returns managed to touch -67.33. Equity return holds the value -64.10%, with -54.90% for asset returns.
The receivables turnover for Zynerba Pharmaceuticals, Inc. is 0.02 with the total asset turnover at the value of 0.00. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.86.
